Validity of the in vitro system as a correlate of the in vivo model of RadLV lymphomagnesis.
Adult BL/6 mice are highly sensitive to lymphomagnesis by the radiation leukemia virus variant A-RadLV (80-100% T-cell lymphoma incidence after a latency of 70-110 days). This study shows that the in vivo elimination of T-cell subsets (including suppressor and cytotoxic T-cells) achieved by the repeated administration of cyclophosphamide, cyclosporin A, anti CD4 or anti CD8 mAb shortly after virus infection did not interfere with the lymphomagenic pathway. No reduction in the high lymphoma incidence or tumor latency was observed following the different treatments. Thus the suggestion on the basis of in vitro studies that the early phase of A-RadLV lymphomagenesis is associated with suppressor T-cells which abrogate a potential anti-tumor immune response has not been confirmed in these studies.
Haran-Ghera
N
N
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
Peled
A
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology; D016827:CD8 Antigens; D003520:Cyclophosphamide / Q000494:pharmacology; D003524:Cyclosporins / Q000494:pharmacology; D004195:Disease Models, Animal; D008212:Lymphocyte Depletion; D016399:Lymphoma, T-Cell / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D016176:T-Lymphocyte Subsets; D014412:Tumor Virus Infections / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D015704:CD4 Antigens; D016827:CD8 Antigens; D003524:Cyclosporins; D003520:Cyclophosphamide